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Abstract: The pharmacokinetics of conventional and long-acting oxytetracycline (OTC) formulation were evaluated in sheep at a
single dosage of 20 mg-kg-1 body weight (bw). Conventional formulation was injected by intravenous (IV) route and long-acting
formulation of oxytetracycline was administered by intramuscular (IM) route. Then blood samples were taken at 0.25, 0.5, 1, 2, 4,
8, 12, 24, 36, 48, 60, 72, 84 and 96 hours. Oxytetracycline analysis was performed by HPLC in plasma. The plasma drug
concentration-time profile was characteristic of a two-compartment open model. Following IM administration, time to reach maximal
plasma drug concentration was 2 hours and maximal plasma drug concentration was 5.13±0.31 µg/ml. After IV and IM
administration of oxytetracycline, the elimination times were 1.14±1.13 and 18.92±1.86 hours, respectively. Intramuscular
bioavailability was found to be 73%. Also, AUC was found to be 106.24±8.92 and 78.92±5.07 µg- ml-1 hours-1, respectively, IV
and IM.
Key Words: Oxytetracycline, long acting, pharmacokinetic.

Oksitetrasiklinin Koyunlarda Geleneksel ve Uzun Etkili Formülasyonlar›n›n
Farmakokineti¤inin Karfl›laflt›r›lmas›
Özet: Bu çal›flmada, koyunlarda oksitetrasiklinin geleneksel ve uzun etkili formülasyonlar›n›n farmakokineti¤i, 20 mg/kg canl› a¤›rl›¤a
olacak flekilde tek doz verilerek de¤erlendirildi. Geleneksel formülasyon damar içi yolla enjekte edildi, uzun etkili formülasyon ise kas
içi yolla verildi. Daha sonra 0.25, 0.5, 1, 2, 4, 8, 12, 24, 36, 48, 60, 72, 84 ve 96. saatlerde kan örnekleri topland›. Plazmada
oksitetrasiklin analiz HPLC ile gerçeklefltirildi. Plazma ilaç yo¤unlu¤u zaman e¤risi 2 bölmeli aç›k modele uygun olarak bulundu. Kas
içi uygulamay› takiben doruk de¤ere ulaflma süresi 2 saat ve doruk ilaç yo¤unlu¤u da 5.13±0.31 µg/ml olarak tespit edildi. Damar
içi ve kas içi yolla oksitetrasiklin uygulamas›ndan sonra at›lma yar› ömrü s›ras›yla, 1.14±1.13 ve 18.92±1.86 saat olarak bulundu.
Kas içi biyoyararlan›m, %73 olarak tespit edildi. Di¤er taraftan AUC, damar içi ve kas içi uygulamalar için s›ras›yla, 106.24±8.92 ve
78.92±5.07 µg/ml/saat olarak belirlendi.
Anahtar Sözcükler: Oksitetrasiklin, uzun etki, farmakokinetik.

Introduction
Oxytetracycline (OTC), obtained from Streptomyces
rimosus, a broad-spectrum antibiotic of the tetracycline
group, is widely used in the treatment of bacterial
diseases in animals (1,2,3). A treatment regimen which
requires repeated injection is time consuming and
expensive, and can be stressful and hazardous,

particularly, but not only, to the patient (4). At present,
parenteral OTC therapy involves daily administrations
over several days. Research has been directed toward
obtaining a depot formulation that would allow a
reduction in the frequency of administration. A longacting formulation of OTC may provide sustained OTC
blood concentration 3 to 5 days after a single IM injection

* This study was presented at the 1st International Conference on Sheep and Goat Diseases and Productivity, Irbid-Jordan.
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(5). There have been many studies on the
pharmacokinetics of OTC in different species (6). Also,
Moreno et al (4) investigated the pharmacokinetics of
OTC with lidocaine after IM administration in sheep.
The objective of this study was to compare, in terms
of pharmacokinetic parameters, a single IM
administration of the long-acting formulation with a
conventional formulation of OTC in sheep.
Materials and Methods
Animals
A total of eight healthy adult Akkaraman sheep
weighing 55-70 kg bw were used. All of the animals were
female and in good health and were housed and fed an
antibiotic-free diet (alfalfa hay and straw) during the
study period. Water was available ad libitum. Animals
were divided into two groups, A and B. Group A (n: 3)
was used for IV studies of conventional formulation of
OTC, and Group B (n:5) was used for IM studies of longacting formulation of OTC.

Assay
Plasma OTC concentrations were determined by HPLC
with a UV detector (Cecil-UK) (7). The column was
ODSC8. 20 µl of filtered fluid was injected into the HPLC
system and scanned at 280 nm. The mobile phase was
composed of 10% acetonitrile (Merck L‹Chrosolv) and
90% water containing KH2PO4 (0.04 M) with the pH
adjusted to 2.5 with a flow rate of 1.0 ml min-1. The
plasma concentration of OTC was calculated by
comparison of the total areas under the chromatographic
peak of experimental plasma samples and standard
calibration curves.
Pharmacokinetic and statistical analysis
The pharmacokinetic parameters were calculated with
the PKCALC computer program (8) on the basis of two
compartment pharmacokinetic models for each animal.
Data obtained from the pharmacokinetic calculations
were analysed statistically by the Mann-Whitney U test
(p<0.05), for which the SPSS Release 8.00 computer
program was used.

Drug administration
Conventional formulation of OTC was prepared just
before IV administration. Oxytetracycline standard was
supplied from ICN Biomedicals Inc. Intravenous injections
were given via the right jugular vein in order to determine
disposition parameters of OTC at a normal injection rate
(<10 s).

Pharmacokinetic constants and parameters
AUC

(µg- ml-1hours-1) Area under the plasma concentrationtime

MRT

(hours)

Mean residence time of drug

Alfa

(hours-1)

Slope of distribution phase

Beta

(hours-1)

Slope of elimination phase

The long-acting formulation contained 200 mg of
OTC hydrochloride/ml. This formulation was supplied
from Pfizer Inc. (Primamycin/LA). Intramuscular
injections were given deep into the gluteal muscles with 6
cm x 2 mm needles.

t1/2 alfa

(hours)

Half-life of drug distribution

Both Group A and Group B sheep were given 20 mg
of OTC/kg of body weight (IM or IV). The IM dose volume
was divided into two parts and 3.5 to 4 ml was injected
per site.
Collection and treatment of samples
Blood samples (a volume of 3 ml) from both groups
were collected from the jugular vein via an injector and
put into heparinized tubes. Collection times for IV and IM
routes were at postinjection hours 0.25, 0.5, 1, 2, 4, 8,
12, 24, 36, 48, 60, 72, 84 and 96. Plasma was
separated by centrifugation at 3000 rpm for 3 minutes,
and stored at –20 °C until assayed.
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curve

t1/2 beta (hours)

Half-life of drug elimination

A1

(µg/ml)

Drug quantity in the central compartment

A2

(µg/ml)

Drug quantity in the peripheral compartment

C max

(µg/ml)

Maximum concentration of drug

T max

(hours)

Time to reach the maximum concentration
of drug

F

(%)

The ratio fraction of the absobed drug

Results
Oxytetracycline plasma concentrations obtained at
different times after IV administration of conventional
formulation were homogeneous and are plotted in
Figures 1 and 2. The oxytetracycline plasma
concentration-time profile was best fitted in all the
animals to the biexponential equation corresponding to
the two-compartment open model.
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Following IM administration, the time to reach
maximal plasma drug concentration was found to be 2
hours, and maximal drug concentration 5.13(0.31 µg/ml.
The elimination half-life was 18.92±1.86 hours, MRT
was 27.69±1.23 hours and AUC0-96 was 78.92±5.07
µg- ml-1hours-1. Intramuscular bioavailability was found
to be 73%. Following IV administration the elimination
half-life was 1.14±1.13 hours, MRT was 12.04±1.13
hours and AUC0-96 was 106.24±8.92 µg-ml-1hours-1
(Table 1).
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Figure 1.

Logarithmic plot of average plasma concentrations of OTC
(mean±SEM) in sheep following the IV administration of
conventional formulation at a single dose of 20 mg kg-1
body weight.
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The long-acting formulation gave a peak value and a
significantly lengthened blood concentration tail. There
was also evidence of a moderate plateau effect in the
long-acting formulation between 4 and 8 hours in that
the mean OTC plasma concentrations remained between
2.480 µg/ml and 2.380 µg/ml. During that period (Table
1) the differences between the mean elimination half-life,
MRT and AUC values of the two groups were highly
significant (p<0.05). A concentration of 0.5 µg/ml was
taken as typical of values which have been used in various
studies, to represent a minimum blood therapeutic
concentration of OTC. The mean values for the
conventional formulation exceeded this concentration for
28 hours, and those for the long-acting formulation for
48 hours. The difference between these two values was
statistically significant (p<0.05).

8—
7—

Discussion

6—

When bacteriostatic drugs such as OTC are
administered, the serum values of the drug should not
decrease below the effective concentrations at any time
during the period of treatment. Because repeated dosage
of OTC is not always practical, a long-acting formulation
was developed to achieve rapid high blood values and to
provide a greater effective serum value over several days
(5). In the present study, the peak plasma concentration
was 5.13±0.31 µg/ml 2 hours after IM administration of
the long acting formulation, decreasing rapidly for 2-4
hours but exceeding 0.20 µg/ml for 96 hours. The
duration of the effective plasma concentration (0.5
µg/ml) in the long-acting formulations was from 36 to 48
hours after IM injections. In other investigations, peak
plasma concentrations of 4.6 µg/ml were obtained at 3
hours (4), 5 µg/ml at 2 hours (9) and 4.30 µg/ml at 4.4
hours after IM injections in sheep. The peak plasma
concentrations and time profile appeared to be similar to
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Figure 2.

Logarithmic plot of average plasma concentrations of OTC
(mean±SEM) in sheep following the IM administration of
long-acting formulation at a single dose of 20 mg kg-1 body
weight.
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Parameters

Units

Primamycin-LA (IM)

Conventional (IV)

AUC(0-96 hours)

µg- ml-1hours-1

78.92±5.07

106.24±8.92*

A1

µg/ml

3.10±0.17

89.60±40.39

A2

µg/ml

-3.10±0.17

-89.60±40.39

MRT

hours

27.69±1.23

12.04±1.13*

Alfa

hours-1

2.77±0.25

0.46±4.14

Beta

-1

hours

0.037±0.16

0.60±0.78

T1/2 alfa

hours

0.25±0.14

1.48±0.69

T1/2 beta

hours

18.92±1.86

1.14±1.13*

C max

µg/ml

5.13±0.31

-

T max

hours

2.0

-

F

%

0.73

Table 1.

Pharmacokinetic
parameters
(mean±SEM) of OTC in sheep
following
administration
of
conventional (IV) and long-acting
(IM) formulation at a single dose of
20 mg kg-1 body weight.

* p<0.05

those reported by Moreno et al. (4) and Pfizer Ref. No
8306 (9). However in the former study, an OTC
formulation with lidocaine was used. Tmax and Cmax have
been reported in different species (6.26 hours and 5.92
µg-ml-1 respectively in cows, according to Meijer et al.,
taken from Moreno et al. (4); 4.62 hours, in goats,
according to Escodero et al., taken from Moreno et.al.
(4). The AUC was lower than the values reported by
Moreno et al (4). Also, the AUC was lower than the values
found in other species (86.2 µg- ml-1hours-1 in goats and
153.11 µg-ml-1hours-1 in cows, according to Escudero et
al. taken from Moreno et.al. (4) and according to Meijer
et al. taken from Moreno et.al. (4), respectively). The
half-life (t1/2β) obtained for long-acting formulation of
OTC in the present study was found to be shorter than in
other studies on the same species (58.24 hours, Moreno
et al., (4). After IV administration of the conventional
formulation of OTC, the values of AUC, t1/2β and MRT
were 106.24±8.92 µg-ml-1hours-1, 1.14±1.13 hours

and 12.04±1.13 hours, respectively. The values of AUC,
t1/2β and MRT of both formulations were different
statistically. The value of AUC for the conventional
formulation was higher than that of the long actingformulation, but, the values of MRT and t1/2β were
shorter. These differences between both formulations
were statistically significant (p<0.05). Also, the duration
of effective plasma concentrations was from 18 to 28
hours. In another study (10), after IV administration of
OTC in sheep, the value of t1/2β was found to be 3.68
hours, which was longer than in the present study.
The data presented for OTC indicate that after IM and
IV administration of equal doses of long-acting and
conventional formulation, an equivalent OTC blood profile
is not produced. The IM administration of long-acting
formulation of OTC provided therapeutic concentrations
for a longer period of time, up to 48 hours. Therefore,
this formulation can be administered every two days.
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